Westford

Researchers are evaluating the safety and effectiveness of the Ultra device for promoting hair regrowth in adults aged 22 to 70 diagnosed with androgenic alopecia. The study focuses on measuring improvements in hair density and hair shaft diameter to assess treatment benefits. Participants include those with Fitzpatrick skin types I through VI and specific patterns of hair loss classified by Norwood-Hamilton or Ludwig scales. Participants will receive six low level laser therapy treatments on the scalp using the Ultra device, with each treatment spaced approximately two weeks apart. No other hair growth treatments, medications, or procedures will be allowed during the study period to ensure clear evaluation of the device's effects. Throughout the study, participants must attend all visits and refrain from significant changes to their hair, diet, or exercise routines. Researchers will monitor changes in hair density from the start of treatment through a 90-day follow-up after the last treatment. Safety and adherence to study requirements will be closely observed during this time.

This research aims to gather clinical data on the use of the Potenza radiofrequency microneedling device to treat various skin conditions where electrocoagulation and hemostasis may help. The study focuses on dermatologic issues such as wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, and loose skin. Up to 12 participants between 22 and 65 years old will take part at a single study center. Participants will be divided into two groups: Group A will receive treatments on the face, neck, and/or body, while Group B will have split-face treatments with different device tips applied to each side. Each participant may receive up to five treatments. A screening or pretreatment visit will occur, possibly on the same day as the first treatment. During the study, participants will attend all scheduled visits and follow study requirements. Researchers will assess safety and treatment satisfaction, measuring the percentage of subjects satisfied with their treatments 30 days after the last session. The study will monitor adherence, any adverse effects, and overall treatment outcomes related to the device's use on soft tissue for dermatologic conditions.